Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Free Cash Flow data on record, last reported at -$27.0 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 38.78% year-over-year to -$27.0 million; the TTM value through Sep 2025 reached -$134.0 million, up 22.16%, while the annual FY2024 figure was -$171.1 million, 17.91% up from the prior year.
  • Free Cash Flow reached -$27.0 million in Q3 2025 per ZNTL's latest filing, up from -$34.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$27.0 million in Q3 2025 and bottomed at -$79.6 million in Q2 2023.
  • Average Free Cash Flow over 4 years is -$42.7 million, with a median of -$39.7 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: plummeted 82.85% in 2023, then soared 55.62% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$37.5 million in 2022, then dropped by 8.76% to -$40.8 million in 2023, then rose by 2.62% to -$39.7 million in 2024, then surged by 32.09% to -$27.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$27.0 million in Q3 2025, -$34.7 million in Q2 2025, and -$32.6 million in Q1 2025.